These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 18212105)

  • 1. In vitro susceptibility of various genotypic strains of Toxoplasma gondii to pyrimethamine, sulfadiazine, and atovaquone.
    Meneceur P; Bouldouyre MA; Aubert D; Villena I; Menotti J; Sauvage V; Garin JF; Derouin F
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1269-77. PubMed ID: 18212105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
    Romand S; Pudney M; Derouin F
    Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
    Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW
    Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
    Alves CF; Vitor RW
    Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an in vitro system to study the developmental stages of Toxoplasma gondii using a genetically modified strain expressing markers for tachyzoites and bradyzoites.
    Portes JA; De Souza W
    Parasitol Res; 2019 Dec; 118(12):3479-3489. PubMed ID: 31728720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic Polymorphisms and Phenotypic Profiles of Sulfadiazine-Resistant and Sensitive Toxoplasma gondii Isolates Obtained from Newborns with Congenital Toxoplasmosis in Minas Gerais, Brazil.
    Silva LA; Reis-Cunha JL; Bartholomeu DC; Vítor RW
    PLoS One; 2017; 12(1):e0170689. PubMed ID: 28118394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfadiazine resistance in Toxoplasma gondii: no involvement of overexpression or polymorphisms in genes of therapeutic targets and ABC transporters.
    Doliwa C; Escotte-Binet S; Aubert D; Sauvage V; Velard F; Schmid A; Villena I
    Parasite; 2013; 20():19. PubMed ID: 23707894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pravastatin and Simvastatin Pretreatment in Combination with Pyrimethamine and Sulfadiazine Reduces Infection Process of Toxoplasma gondii Tachyzoites (RH Strain) in HeLa Cells.
    Sanfelice RADS; da Silva SS; Bosqui LR; Machado LF; Miranda-Sapla MM; Panagio LA; Navarro IT; Conchon-Costa I; Pavanelli WR; Almeida RS; Costa IN
    Acta Parasitol; 2019 Sep; 64(3):612-616. PubMed ID: 31286354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of sulfadiazine resistance in vitro in Toxoplasma gondii.
    Doliwa C; Escotte-Binet S; Aubert D; Velard F; Schmid A; Geers R; Villena I
    Exp Parasitol; 2013 Feb; 133(2):131-6. PubMed ID: 23206954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro generation of novel pyrimethamine resistance mutations in the Toxoplasma gondii dihydrofolate reductase.
    Reynolds MG; Oh J; Roos DS
    Antimicrob Agents Chemother; 2001 Apr; 45(4):1271-7. PubMed ID: 11257045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro effects of sulfadiazine and its metabolites alone and in combination with pyrimethamine on Toxoplasma gondii.
    Schoondermark-van de Ven E; Vree T; Melchers W; Camps W; Galama J
    Antimicrob Agents Chemother; 1995 Mar; 39(3):763-5. PubMed ID: 7793889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.
    Derouin F; Santillana-Hayat M
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2575-7. PubMed ID: 10952623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.
    Mack DG; McLeod R
    Antimicrob Agents Chemother; 1984 Jul; 26(1):26-30. PubMed ID: 6383209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azithromycin treatment is able to control the infection by two genotypes of Toxoplasma gondii in human trophoblast BeWo cells.
    Ribeiro M; Franco PS; Lopes-Maria JB; Angeloni MB; Barbosa BF; Gomes AO; Castro AS; Silva RJD; Oliveira FC; Milian ICB; Martins-Filho OA; Ietta F; Mineo JR; Ferro EAV
    Exp Parasitol; 2017 Oct; 181():111-118. PubMed ID: 28803905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxoplasma gondii: the effect of fluconazole combined with sulfadiazine and pyrimethamine against acute toxoplasmosis in murine model.
    Martins-Duarte ÉS; de Souza W; Vommaro RC
    Exp Parasitol; 2013 Mar; 133(3):294-9. PubMed ID: 23270807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinonic derivatives active against Toxoplasma gondii.
    Sarciron ME; Nebois P; Pautet F; Pétavy AF; Fillion H; Walchshofer N
    Parasitol Res; 2002 Nov; 88(11):969-71. PubMed ID: 12375161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
    Araujo FG; Lin T; Remington JS
    J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo susceptibility to sulfadiazine and pyrimethamine of Toxoplasma gondii strains isolated from Brazilian free wild birds.
    de Lima Bessa G; Vitor RWA; Lobo LMS; Rêgo WMF; de Souza GCA; Lopes REN; Costa JGL; Martins-Duarte ES
    Sci Rep; 2023 May; 13(1):7359. PubMed ID: 37147353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance.
    McFadden DC; Tomavo S; Berry EA; Boothroyd JC
    Mol Biochem Parasitol; 2000 Apr; 108(1):1-12. PubMed ID: 10802314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro.
    Wang JL; Elsheikha HM; Li TT; He JJ; Bai MJ; Liang QL; Zhu XQ; Cong W
    Int J Antimicrob Agents; 2019 Dec; 54(6):814-819. PubMed ID: 31479744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.